阿达木单抗在类风湿性关节炎中的应用综述。

文章的细节

引用

复制到剪贴板

Bang LM, Keating总经理

阿达木单抗在类风湿性关节炎中的应用综述。

BioDrugs。2004; 18(2): 121 - 39。

PubMed ID

15046527 (PubMed视图

］

摘要

Adalimumab (Humira)是一种重组的完全人IgG1单克隆抗体，特异性结合肿瘤坏死因子(TNF) α，从而中和细胞因子的活性。皮下阿达木单抗已经在精心设计的试验中被研究用于活动性类风湿关节炎患者，尽管他们已经接受了疾病修饰抗风湿药物(dmard)的治疗。每隔一周接受阿达木单抗40mg联合甲氨蝶呤(单抗阿达木单抗抗tnf研究项目[ARMADA]和DE019试验)或标准抗风湿病治疗(阿达木单抗类风湿性关节炎安全性试验[STAR]试验)24-52周的必威国际app患者，与接受安慰剂+甲氨蝶呤或标准抗风湿病治疗的患者相比，美国风湿病学会(ACR) 20、ACR50和ACR70的反应率显著更高。在ARMADA研究中，25%、52%和67%的阿达木单抗+甲氨蝶呤受体分别在第1周、第4周和第24周达到ACR20应答。在ARMADA和DE019中，每隔一周阿达木单抗40mg加甲氨蝶呤组ACR反应的各个成分的改善明显大于安慰剂加甲氨蝶呤组。与安慰剂相比，每隔一周使用阿达木单抗40mg单药治疗与ACR20、ACR50和ACR70应答率显著升高相关，并且ACR应答的各个组分有显著改善。根据扩展研究的结果，阿达木单抗与甲氨蝶呤联合治疗(长达30个月)或单药治疗(长达5年)的患者ACR反应持续。在伴随治疗和单药治疗试验中，阿达木单抗与基线相比，与健康相关的生活质量(HR-QOL)指标有更大的改善;与安慰剂相比，阿达木单抗还在很大程度上延缓了结构性关节损伤的影像学进展。阿达木单抗作为伴随治疗和单药治疗通常耐受良好。 In ARMADA, there were no significant differences between adalimumab and placebo (in combination with methotrexate) in the incidence of adverse events; however, in STAR, the incidence of injection site reactions, rash, and back pain was significantly higher with adalimumab than with placebo (in combination with standard antirheumatic therapy). No cases of tuberculosis were reported in either trial.In conclusion, subcutaneous adalimumab in combination with methotrexate or standard antirheumatic therapy, or as monotherapy, is effective in the treatment of adults with active rheumatoid arthritis who have had an inadequate response to DMARDs. Adalimumab has a rapid onset of action and sustained efficacy. The drug also retards the progression of structural joint damage, improves HR-QOL, and is generally well tolerated. Thus, adalimumab is a valuable new option for the treatment of DMARD-refractory adult rheumatoid arthritis.

引用本文的药物库数据

药物靶点

药物	目标	种类	生物	药理作用	行动
Adalimumab	肿瘤坏死因子	蛋白质	人类	是的	抑制剂 抗体	细节